ABOUT 16th_ELSF
> REGISTRATION​
​> AGENDA​
​> ATTENDEES​
​> INVESTORS​
​> PRESENTERS​
​> SPONSORS​
​> SUPPORTERS​
​> NETWORKING​
> VENUE​
> ACCOMMODATION​

> ABOUT LAST YEAR​

For the first time since the pandemic started, we are pleased to announce that the 16th Annual European Life Sciences CEO Forum (ELSF) will take place In-Person on the 1st - 2nd March 2023 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate the 4th Annual European HealthTech CEO Forum.

The success and longevity of the forum is built on the goodwill and repeat attendance of major corporate and financial investors, and pharma licensing executives and advisors, who are seeking to network with biotechs. The programme and presentations allow all to keep up with the latest industry developments and strategize for 2023. The physical programme will consist of the usual panels and keynotes, which will be available on demand from the 8th of March. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases and a reception. During the online week, virtual meetings will be available through the audio/video online meeting system.

The main programme for the 16th Annual ELSF is spread throughout 2 days (1st - 2nd of March) and will feature more than 12 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, banks and advisors with part of the audience participating virtually.

The In-Person meetings will be taking place on the 1st - 2nd of March, while virtual meetings will take place on the 8th - 10th of March. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as option to present slides using a screen share function and we will have a dedicated room for in-person meetings. We expect 2000+ meetings completed during SSLSW. The conference will be held in the Central European Time Zone. The programme will consist of:

Day 1 (Wednesday, 1st of March)

• Prospects for Biopharma in 2023 Panel
• Outlook for Global Venture & Private Equity Panel
• Platform & New Technologies Panel
• Cell & Gene Therapies: Latest Therapeutic Advances Panel
  
• Neuro Advances Panel
• The IRA and Implications for the BioPharma Industry Panel

Day 2 (Thursday, 2nd of March)

• Pharma Dealmakers Roundtable
• Latest Trends in Oncology BD&L Panel
• Oncology Advanced Therapeutics Panel
• Early Stage Investor Panel
• Presenting Company Session: Biopôle Selected Investment Opportunities
• Rising Biotech Stars Session

In-Person Meetings - 1st - 2nd of March
Virtual Meetings via Online Meeting System - 8th - 10th of March
Networking Reception - 1st of March
On-Demand Content – from 8th of March

Confirmed Chairs & Speakers Include:

• Adrian Dawkes, Managing Director, PharmaVentures Ltd. 
• Andrea Patricelli Malizia, CEO, IAMA Therapeutics S.r.l.
• Andreas Jurgeit, Partner, Gimv
• Andrew Sinclair, Managing Director, Abingworth LLP
• Andrin Oswald, Incoming CEO, Somagenetix AG
• Apollon Papadimitriou, CEO, IOmx Therapeutics AG
• Brian Hashemi, Executive Chairman & CEO, Novigenix SA
• Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A.
• Carlos de Sousa, CEO, Ultimovacs ASA
• Chandra Leo, Investment Advisor, HBM Partners AG
• Chris Garabedian, Chairman & CEO, Xontogeny*
• Dani Bach, Partner, +ND Capital
• Dmitrij Hristodorov, Partner, Forbion
• Duncan Young, Head of BD, Redx Pharma Plc.
• Ellen Licking, Senior Director, Client Services & Communications, Real Endpoints LLC*
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Fabian Buller, CBO, Neurimmune AG
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Gita Dittmar, Executive Chair, Twelve Bio ApS
• Gregor Macdonald, VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S
• Göran Forsberg, CEO, Cantargia AB
• Hans Herklots, Managing Director, Second Thought
• Isabel Ferreira, Chief Business Officer, Versameb AG
• Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc.
• John Stanford, Executive Director, Incubate*
• Katya Smirnyagina, Senior Partner (Life Sciences), Oxford Science Enterprises
• Kelly Curtin, Managing Director, Torreya
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Klaus Breiner, Managing Partner, Pureos Bioventures
• Kristen Albright, CEO, Prokarium Ltd.
• Lubor Gaal, CFO, Targovax ASA
• Lynn Durham, CEO, STALICLA SA
  
• Markus Hosang, General Partner & Managing Director, BioMedPartners AG
• Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA, Darmstadt, Germany
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Huebner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
• Miguel Silva, Director of Strategy, OMass Therapeutics
• Miquel Vila-Perelló, CEO, SpliceBio S.L
• Modi Teicher, Chief Business Officer, FutuRx
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nicki Thompson, CEO, Amphista Therapeutics Ltd.
• Olav Zilian, Senior Equity Analyst - Healthcare, Pictet & Cie SA
• Paul Hermant, Partner, Bird & Bird LLP
• Paul Rennert, CEO, President & CSO, Aleta Biotherapeutics
• Peter Braun, CEO, TargImmune Therapeutics AG
• Peter Llewellyn-Davies, CEO & CFO, invIOs GmbH
• Pierre-Jean Wipff, Director Innovation & Partnerships, Biopôle SA
• Rao Movva, Novartis Distinguished Scientist & Independent Pharma & Biotech Advisor
• Regina Hodits, Managing Partner, Wellington Partners
• Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
• Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
• Ryan Richardson, Chief Strategy Officer, BioNTech SE
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sascha Berger, General Partner, TVM Capital Life Science
• Shuguang Yuan, CEO,  AlphaMol Science AG
• Søren Bregenholt, CEO, Alligator Bioscience AB
• Søren Møller, Managing Partner, Novo Holdings A/S
• Stephanie Léouzon, Partner & Head of Europe, Torreya
• Stephen Myatt, CEO, Macomics Ltd.
• Steve Dickman, CEO, CBT Advisors
• Tamas Schweighoffer, Co-Founding Partner, Forty51 Ventures
• Thibaut Roulon, Senior Investment Director, Bpifrance
• Thierry Laugel, Managing Partner, Kurma Partners
• Thilo Schroeder, Managing Partner, Nextech Invest Ltd.
• Thomas Hoeger, CEO, Apogenix AG
• Thomas Tan, Principal, Sound Bioventures Management AB
• Zaki Salanti, Senior Director, Head of Search & Evaluation, Novo Nordisk A/S
• More TBA...

* Virtual Speaker

Confirmed Presenters Include:

PARTICIPATION OPTIONS:

Complimentary passes are provided for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however the organiser has the discretion to reject registrations. Other participants may consider purchasing access, which includes in-person or virtual participation, with different options to showcase your company.

NETWORKING OPPORTUNITIES:

The Online Meeting System will open on the 14th of February for uploading profiles and sending meeting invites. The in-person meetings will be taking place on the 1st - 2nd of March, while virtual meetings will take place on the 8th - 10th of March . For the virtual meetings, the system will allow you to have a secure audio/video call, as well as an option to present slides using a screen share function and we will have a dedicated room for in-person meetings.

PRESENTING OPPORTUNITIES:

Presentations are a popular and useful way to gain additional exposure with potential investors and pharma partners, which make up over half the audience. We are pleased to announce that once again we will have 20-minute and 10-minute presentations taking place in-person at the dedicated presenting tracks. Here you will be able to showcase your company in front of investors attending the physical event. The recording will be added to your company’s profile later, which will be available on demand for registered participants until the event portal closes. Start-up companies, which are looking for seed financing can apply for a Rising Stars – Seed Companies Session.

For those who are not able to present in-person, but are still interested to showcase their company, there is an option to purchase either a 20 or 10 minute presentation, which will be pre-recorded in advance and available to all registered attendees on the event’s portal. Start-up companies may also purchase a 5-minute pre-recorded showcase instead.

The Sachs Team can assist with the pre-recording of the presentation, or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.

EXHIBITING OPPORTUNITIES: 

Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships.

If attending the physical event, we have a limited number (limited to 3 companies) of table-top exhibitions available at the venue, which would be located at the main foyer, next to the plenary room, where we have the highest attendee traffic.

For those who are not able to join the event or exhibit in-person, you could choose virtual exhibition package, which includes a dedicated virtual page, where we can: upload your branded company’s profile and list ways to reach you; share video or images about services you provide and have files ready for download, if you wish to share any additional information with potential clients.

If interested in learning more about exhibition options, please fill in the registration form.

SPONSORING OPPORTUNITIES: 

There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising, and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.

To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.

Silver Sponsors:

---

Bronze Sponsors:

---

Contributing Sponsors:

---

Supporters:

---

Participating Pharmas:

---

Financial, Advisory & Investors Attending:

+ND Capital
3B Future Health Ventures
AbbVie Ventures
Abingworth LLP
AFK & Partners Asset Management LLC
AGTC Ventures LLC
AMR Action Fund GP GmbH
Anchor
Andera Partners
Apollo Health Ventures
ARTO AG
ATGN Consulting
Atlas Capital Markets
Atlas Capital Ventures LLC
AXA Investment Managers
BERNINA BioInvest Ltd.
BGV (BioGeneration Ventures)
BioMedPartners AG
BiomedVC AG
Bioqube Ventures
BIOSTART Consulting GmbH
Boehler Life Science Advice
Bootstrap Europe
Bpifrance
Breslin AG & LSFA
BROTHERS & Partners Europe
Canica Holding AG
Capricorn Partners
CD-Venture GmbH
Columbus Venture Partners
Convergence Partners AG
Corinthian Financial Management SARL
Delin Ventures
Digital Networks Plc. S.r.l.
Eliraz Ventures
Forbion
Forty51 Ventures
FutuRx
Gimv
Global Life Science Ventures GmbH
GrayBella Capital LLC
H.C. Wainwright & Co., LLC
HBM Partners AG
High-Tech Gründerfonds Management GmbH
Hitachi Ventures GmbH
HitchinRock Advisors Limited
ICF Consult Switzerland
Indaco Venture Partners SGR
Indaco Venture Partners SGR S.p.A.
Industrifonden
Inflexion Private Equity Partners
Inveready

To View All - Click Here